

High-Impact Clinical Trials

Hall J

Moderators:

Sharon G. Adler, MD, FASN, and Janice P. Lea, MD, MS, FASN

-
- 10:30 a.m.**
SA-OR121 **Tolvaptan Slows eGFR Decline in Later-Stage ADPKD—***Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Ronald D. Perrone, Gary G. Koch, John Ouyang, Robert D. Mcquade, Jaime Blais, Frank S. Czerwiec, Olga Sergeyeva*
- 10:47 a.m.**
SA-OR122 **Bardoxolone Methyl Improved GFR Measured by Standard Inulin Clearance: The TSUBAKI Study—***Masaomi Nangaku, Ryutaro Shimazaki, Tadao Akizawa*
- 11:04 a.m.**
SA-OR123 **Kidney Injury After Intravenous or Intracoronary Contrast Agents for Noninvasive or Invasive Coronary Angiography: An Industry-Independent, Phase 3, Randomized Controlled Trial—***Marc Dewey, Peter Martus, Maria Bosserd, Elke Zimmermann, Michael Laule, Eva Schönenberger*
- 11:21 a.m.**
SA-OR124 **Efficacy and Safety of QPI-1002 (QPI) for Prevention of AKI Following Cardiac Surgery—***David Corteville, Robert J. Still, Gabor Szabo, Madhav Swaminathan, Vasant Jayasankar, Andre Lamy, Lukas J. Lehner, Matthias Thielmann, Craig D. Brown, Ec Squiers, U. Schwertschlag, A. Potts, A. Patel, E.K. Messersmith, D. Rothenstein, D.J. Odenheimer, S. Erlich*
- 11:38 a.m.**
SA-OR125 **The Pivotal Multicenter Trial of Ultrasound Guided Percutaneous Arteriovenous Fistulae for Hemodialysis Access—***Jeffrey E. Hull, William C. Jennings, Randy I. Cooper, Umar Waheed, Matthew E. Schaefer, Rajeev Narayan*
- 11:55 a.m.**
SA-OR126 **Primary Results of the Time to Reduce Mortality in End-Stage Renal Disease (TiME) Trial: A Pragmatic Trial Demonstration Project of the NIH Health Care Systems Research Collaboratory—***Laura M. Dember, Eduardo K. Lacson, Steven M. Brunelli, Jesse Y. Hsu, Alfred K. Cheung, John T. Daugirdas, Tom Greene, Csaba P. Kovesdy, Dana Miskulin, Ravi I. Thadhani, Wolfgang C. Winkelmayer, Allen R. Nissenson, Franklin W. Maddux, Michael F. Flessner, Kevin C. Abbott, J. R. Landis*
- 12:12 p.m.**
SA-OR127 **A Multi-Center Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR)—***Fernando C. Fervenza, Pietro A. Canetta, Sean Barbour, Richard A. Lafayette, Brad H. Rovin, Nabeel Aslam, Michelle A. Hladunewich, Heather N. Reich, Paul E. Brenchley, Debbie S. Gipson, Matthias Kretzler, Jai Radhakrishnan, Lee A. Hebert, Patrick E. Gipson, Leslie F. Thomas, Ellen T. McCarthy, Gerald B. Appel, J. Ashley Jefferson, Nelson Leung, Daniel C. Cattran*
- 12:30 p.m.** **Adjourn**

Late-Breaking Clinical Trial Posters

Hall G

- FR-PO1053 **Initial Data Report from “CARDINAL”: A Phase 2/3 Study of Bardoxolone Methyl in Patients with Alport Syndrome**—*Geoffrey A. Block, Pablo E. Pergola, Lesley Inker, Peter A. McCullough, Melanie Chin, Colin J. Meyer, Michelle N. Rheault, Clifford E. Kashtan, David G. Warnock*
- FR-PO1054 **A Phase 1/2 Trial of ALN-GO1: An Investigational RNAi Therapeutic for Primary Hyperoxaluria Type 1**—*Yaacov Frishberg, William van't Hoff, Sally Hulton, Patrick Haslett, David V. Erbe, Tracy McGregor, Georges Deschênes*
- FR-PO1055 **Abstract Withdrawn**
- FR-PO1056 **IV Cyclophosphamide vs Tacrolimus and Azathioprine as Induction in Proliferative Lupus Nephritis: A Randomized Controlled Trial**—*Arpita Roychowdhury, Dipankar Sircar*
- FR-PO1057 **Rituximab (RTX) Treatment of Fibrillary Glomerulonephritis (FGN): A Pilot Study**—*Stephen B. Erickson, Mariam P. Alexander, Samih H. Nasr, Fernando C. Fervenza*
- FR-PO1058 **Canagliflozin and Renal Outcomes in Type 2 Diabetes: Data from the CANVAS Program**—*Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D. Barrett, Michele Weidner-Wells, Hsiaowei Deng, Norm Rosenthal, Mehul Desai, David R. Matthews, Bruce Neal*
- FR-PO1059 **Vascular Adhesion Protein-1 Inhibitor (VAP-1i) Reduces Albuminuria in Diabetic Kidney Disease**—*Dick de Zeeuw, Ronny Renfurm, Tobias E. Larsson*
- FR-PO1060 **Abstract Withdrawn**
- FR-PO1061 **Abstract Withdrawn**
- FR-PO1062 **A Multicentre, Stepped-Wedge Cluster Randomised Trial of a Complex Intervention to Reduce Harm Associated with AKI**—*Nicholas M. Selby, Anna Casula, Laura Lamming, John Stoves, Yohan P. Samarasinghe, Andrew J. Lewington, Russell Roberts, Nikunj Shah, Richard J. Fluck, Mel J. Johnson, Natalie Jackson, Carol A. Jones, Fergus J. Caskey*
- FR-PO1063 **Fenoldopam in in Shiga Toxin-Related Hemolytic Uremic Syndrome**—*Gianluigi Ardissino, Antenore Giussani, Francesca Tel, Sara Testa, Fabio Paglialonga, Silvia Consolo, Cristiano Gandini, Luisa Napolitano, Emilio Fossali, Dario Consonni*
- FR-PO1064 **Results of a Randomized Multicentre Pilot Study of Sacubitril/Valsartan versus Irbesartan in Patients with CKD: United Kingdom Heart and Renal Protection (UK HARP)-III Trial**—*Richard Haynes, Parminder K. Judge, Natalie Staplin, Martin J. Landray, Colin Baigent*
- FR-PO1065 **Aspirin Treatment in Primary Cardiovascular Prevention and Renal Disease Progression in CKD Patients: A Randomized Clinical Trials (AASER Study)**—*Marian Goicoechea, Maria soledad Garcia de vinuesa, Borja Quiroga, Ursula Verdalles, Enrique Morales, Patricia De Sequera, Gema Fernandez Juarez, Eduardo Verde, Jose Luno*
- FR-PO1066 **CKD Antidepressant Sertraline Trial (CAST)**—*Susan Hedayati, Lucile Parker Gregg, Thomas Carmody, Nishank Jain, Marisa S. Touns, Augustus J. Rush, Robert D. Toto, Madhukar Trivedi*
- FR-PO1067 **Rapid Bedside Plasma Volume (PV) and Measured GFR (mGFR) in Normal and CKD Subjects**—*Dana Rizk, Daniel Meier, Ruben M. Sandoval, Teresa Chacana, Erinn S. Reilly, Jesse C. Seegmiller, Emanuel Denoia, James S. Strickland, Joseph Muldoon, Bruce A. Molitoris*
- FR-PO1068 **Effect of Drinking More Water on Kidney Function Decline in Adults with CKD: A Randomized Clinical Trial**—*William F. Clark*
- FR-PO1069 **An Integrated Smartphone Application Improves Patient Safety and Intervention Adherence: A Randomized Controlled Trial (RCT) with an Active Control Group**—*Sarbjit V. Jassal, Stephanie W. Ong, Kelly Min, Akib Uddin, Eveline C. Porter, Joseph A. Cafazzo, Emily Seto, George Tomlinson, Alexander G. Logan*
- FR-PO1070 **DIALOGUE Phase 2 Extension Studies of BAY 85-3934, Molidustat, a HIF-PH Inhibitor with Daily Oral Treatment in Anemic Subjects with CKD**—*Tadao Akizawa, Iain C. Macdougall, Jeffrey S. Berns, Thomas Bernhardt, Thilo Krueger, Megumi Taguchi, Eriko Ogura, Kazuma Iekushi*

- FR-PO1071 **Head-to-Head Efficacy and Safety Comparisons of a Novel Calcimimetic Agent (Evocalcet) with Cinacalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: A Randomized Clinical Trial—***Masafumi Fukagawa, Ryutaro Shimazaki, Tadao Akizawa*
- FR-PO1072 **Effect of Phosphate Binders on Biochemical and Vascular Outcomes in Patients with Non-Dialysis Dependent CKD—***Csaba P. Kovcsdy, Jun Ling Lu, Zhongji Han, Fridtjof Thomas, Leigh D. Quarles, Nabil Jarmukli*
- FR-PO1073 **Comparison of Lanthanum Carbonate with Calcium Carbonate for the Progression of Coronary Artery Calcification in Hemodialysis Patients—***Hiroaki Ogata, Masafumi Fukagawa, Hideki N. Hirakata, Tatsuo Kagimura, Tadao Akizawa*
- FR-PO1074 **Efficacy and Safety of Short-Term Treatment with Sodium Zirconium Cyclosilicate (ZS-9) for Hyperkalemia: Open-Label, Phase 3 Trial—***David K. Packham, Steven Fishbane, Pablo E. Pergola, Edgar V. Lerma, Javed Butler, Stephan Von haehling, Scott H. Adler, Bhupinder Singh, Philip T. Lavin, Peter A. McCullough, Mikhail Kosiborod, Bruce S. Spinowitz*
- FR-PO1075 **Novel Intermittent Pneumatic Compression Device Promotes Early Cannulation—***Tej M. Singh*
- FR-PO1076 **Prospective, Randomized, Multi-Center, Double-Blind, Controlled, Two-Period, Two-Treatment, Crossover, Phase II Trial to Evaluate the Safety and Efficacy of Alanine-Glutamine in Peritoneal Dialysis—***Andreas Vychytil, Klaus Kratochwill, Rebecca Herzog, Christoph Aufricht*
- FR-PO1077 **Twelve Weeks of Home-Based Exercise Training Improves Strength, Function and Quality-of-Life Measures in Elderly Hemodialysis Patients—***Khin N. Chan, Payam Massaband, Yiming Lit, Yu Chen, Tieming Niu, Jonathan N. Myers*
- FR-PO1078 **Safety and Cardiovascular Efficacy of Spironolactone (SPL) in Dialysis-Dependent ESRD (SPin-D): A Pilot Trial of the NIDDK Hemodialysis Novel Therapies Consortium—***David M. Charytan, Jonathan Himmelfarb, Talat Alp Ikizler, Dominic S. Raj, Jesse Y. Hsu, J. R. Landis, Paul L. Kimmel, John W. Kusek, Alan S. Kliger, Laura M. Dember*
- FR-PO1079 **Effect of Hemodialyzer Characteristics on the Prognosis of Elder Dialysis Patients with Early Dialysis Stage (E-HOPED Study)—***Ikuto Masakane, Jun Minakuchi, Hideki Kawanishi, Kosaku Nitta*

Posters will be on display during exhibit hall hours (9:30 a.m. – 2:30 p.m.).